Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M94,330Revenue (TTM) $M37,472Net Margin (%)1.1Altman Z-Score1.2
Enterprise Value $M115,895EPS (TTM) $0.1Operating Margin %6.6Piotroski F-Score4
P/E(ttm)258Beneish M-Score-2.7Pre-tax Margin (%)4.1Higher ROA y-yN
Price/Book55310-y EBITDA Growth Rate %1.7Quick Ratio0.7Cash flow > EarningsY
Price/Sales2.85-y EBITDA Growth Rate %7.6Current Ratio1.0Lower Leverage y-yY
Price/Free Cash Flow27.7y-y EBITDA Growth Rate %-76.5ROA % (ttm)0.5Higher Current Ratio y-yN
Dividend Yield %5.4PEG33.9ROE % (ttm)10.7Less Shares Outstanding y-yN
Payout Ratio %1,373Shares Outstanding M2,436ROIC % (ttm)5.0Gross Margin Increase y-yN

Gurus Latest Trades with GSK

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
GSKKen Fisher 2016-12-31 Reduce$37.39 - $43.44
($39.52)
$ 38.72-2%Reduce -0.44%11,809,500
GSKKahn Brothers 2016-09-30 Add1.98%$42.5 - $45.49
($43.86)
$ 38.72-12%Add 66.18%632,040
GSKCharles Brandes 2016-09-30 Reduce-0.46%$42.5 - $45.49
($43.86)
$ 38.72-12%Reduce -16.54%3,525,668
GSKNWQ Managers 2016-09-30 Add0.37%$42.5 - $45.49
($43.86)
$ 38.72-12%Add 28.09%2,658,155
GSKHOTCHKIS & WILEY 2016-09-30 Reduce-0.05%$42.5 - $45.49
($43.86)
$ 38.72-12%Reduce -3.42%8,150,402
GSKKen Fisher 2016-09-30 Add0.01%$42.5 - $45.49
($43.86)
$ 38.72-12%Add 1.11%11,861,172
GSKBarrow, Hanley, Mewhinney & Strauss 2016-09-30 Reduce$42.5 - $45.49
($43.86)
$ 38.72-12%Reduce -6.59%235,200
GSKDodge & Cox 2016-09-30 Reduce$42.5 - $45.49
($43.86)
$ 38.72-12%Reduce -5.20%41,962
GSKJoel Greenblatt 2016-09-30 Reduce$42.5 - $45.49
($43.86)
$ 38.72-12%Reduce -2.22%25,284
GSKTweedy Browne 2016-09-30 Reduce$42.5 - $45.49
($43.86)
$ 38.72-12%Reduce -1.41%114,844
GSKKahn Brothers 2016-06-30 Add2.08%$40.04 - $43.47
($42.12)
$ 38.72-8%Add 188.24%380,335
GSKNWQ Managers 2016-06-30 Add1.17%$40.04 - $43.47
($42.12)
$ 38.72-8%Add 316.61%2,075,187
GSKCharles Brandes 2016-06-30 Reduce-0.14%$40.04 - $43.47
($42.12)
$ 38.72-8%Reduce -5.59%4,224,506
GSKHOTCHKIS & WILEY 2016-06-30 Reduce-0.08%$40.04 - $43.47
($42.12)
$ 38.72-8%Reduce -5.34%8,439,389
GSKKen Fisher 2016-06-30 Add0.01%$40.04 - $43.47
($42.12)
$ 38.72-8%Add 0.63%11,730,875
GSKJohn Rogers 2016-06-30 Add0.01%$40.04 - $43.47
($42.12)
$ 38.72-8%Add 1.57%1,607,697
GSKJoel Greenblatt 2016-06-30 Reduce-0.01%$40.04 - $43.47
($42.12)
$ 38.72-8%Reduce -49.63%25,857
GSKTweedy Browne 2016-06-30 Add$40.04 - $43.47
($42.12)
$ 38.72-8%Add 0.36%116,491
GSKDodge & Cox 2016-06-30 Reduce$40.04 - $43.47
($42.12)
$ 38.72-8%Reduce -45.53%44,262
GSKHOTCHKIS & WILEY 2016-03-31 Reduce-0.52%$38.54 - $42.05
($39.84)
$ 38.72-3%Reduce -26.34%8,915,323
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

GSK is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


GSK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GLAXOSMITHKLINE PLCFormer 10% Owner 2015-02-23Sell503,150$2276view
GLAXOSMITHKLINE PLC10% Owner 2014-12-18Sell50,000$21.1483.16view
GLAXOSMITHKLINE PLCFormer 10% Owner (1) 2014-10-27Sell11,315,825$5.29631.95view
GLAXOSMITHKLINE PLC10% Owner 2014-04-01Buy103,762$12222.67view
GLAXOSMITHKLINE PLCFormer 10% Owner 2014-02-19Buy35,000$14176.57view
GLAXOSMITHKLINE PLCFormer 10% Shareholder 2014-02-10Buy143,773$12222.67view

Press Releases about GSK :

Quarterly/Annual Reports about GSK:

    News about GSK:

    Articles On GuruFocus.com
    Flood of News Presents Buying Opportunity Jan 17 2017 
    Gilead Sciences Must Answer to Investors After a Disappointing 2016 Jan 05 2017 
    GlaxoSmithKline, Vodafone Hit 3-Year Low Prices Dec 24 2016 
    Asset Sales, New Projects Fuel 6.7% Yield Dec 07 2016 
    Robust Pipeline Supports 5.5% Dividend Yield Dec 05 2016 
    Jeff Auxier Curbs Multiple Positions in 3rd Quarter Dec 01 2016 
    Tweedy Browne Fund Investment Adviser's Semi-Annual Letter to Shareholders Nov 28 2016 
    6 Worthy Dividend Stocks Down 10% or More Nov 22 2016 
    Kahn Brothers Adds to 4 Holdings in 3rd Quarter Nov 02 2016 
    Tweedy Browne Adds to 5 Holdings, Trims 2 Others in 3rd Quarter Oct 11 2016 

    More From Other Websites
    3 Footsie giants you should consider buying before it’s too late Jan 21 2017
    Novartis’s 4Q16 Earnings: What Is Expected? Jan 20 2017
    Is GlaxoSmithKline (GSK) a Great Stock for Value Investors? Jan 20 2017
    Why is Pharma Struggling to Grow EPS? Jan 19 2017
    Glaxo CEO Seeks Greater Transparency on Drug Pricing Jan 19 2017
    GSK grabs Astra executive to replace pharma head Jan 19 2017
    GSK grabs Astra executive to replace pharma head Jan 19 2017
    GSK grabs Astra executive to replace pharma head Jan 19 2017
    GSK grabs Astra executive to replace exiting pharma head Jan 19 2017
    GSK grabs Astra executive to replace exiting pharma head Jan 19 2017
    GSK grabs Astra executive to replace exiting pharma head Jan 19 2017
    GSK grabs Astra executive to replace exiting pharma head Jan 19 2017
    Ebola, Zika Push Drugmakers Into Effort to Avert Pandemics Jan 18 2017
    In This Case Silence Could be Golden Jan 17 2017
    Does this pharma’s 56% sales growth make it a better buy than GlaxoSmithKline plc? Jan 17 2017
    5 Trump-Proof Pharma Dividends Up To 5.3% Jan 16 2017
    How Does Novartis’s Valuation Compare to Peers? Jan 16 2017
    Two 5% dividend yields you’d be crazy to pass up Jan 15 2017
    Full Show: What'd You Miss? (01/11) Jan 11 2017
    GlaxoSmithKline's Redfern on Drug Pricing Jan 11 2017
    GlaxoSmithKline's Redfern on Drug Pricing Jan 11 2017
    Does EKF Diagnostics Holding plc have more upside than GlaxoSmithKline plc after beating... Jan 09 2017
    Adaptimmune confirms GSK Nomination of Second Adaptimmune Target under Strategic Multi-Target... Jan 09 2017
    NeRRe, A GlaxoSmithKline PLC (ADR) (GSK) Spinout Raises £23 Million For NK Antagonists Jan 06 2017
    Bristol-Myers, J&J Ink Immunotherapy Research Collaboration Jan 06 2017
    Mylan, Novartis, Hikma Take On GSK In Generic Asthma Battle Jan 05 2017
    Is today’s 10% riser Churchill China plc the perfect way to profit from Brexit? Jan 05 2017
    Are these the ultimate safety shares for a turbulent 2017? Jan 04 2017
    GlaxoSmithKline Plc : GSK-US: Dividend Analysis : November 04th, 2016 (record date) : By the numbers... Jan 03 2017
    Total Voting Rights Jan 03 2017
    GSK confirms closure of agreement to divests non-core assets to Aspen Jan 03 2017
    2 beginner stocks to kick-start a portfolio Jan 03 2017
    Top stocks for January Jan 01 2017
    Why I’m bullish on GlaxoSmithKline plc for 2017 Dec 30 2016
    FTSE 100 clocks all-time closing high Dec 29 2016
    Is this under-the-radar pharma stock the next GlaxoSmithKline plc? Dec 28 2016
    GSK launches big study to test new injection for HIV prevention Dec 20 2016
    GSK's two-drug HIV therapy shines in two big studies Dec 20 2016
    GSK's two-drug HIV therapy shines in two big studies Dec 20 2016
    Blocklisting Application Dec 20 2016
    3 stocks you can buy with dividends yielding more than 5% Dec 20 2016
    GSK boosts board-level science as new CEO prepares to take over Dec 19 2016
    GSK boosts board-level science as new CEO prepares to take over Dec 19 2016
    GSK boosts board-level science as new CEO prepares to take over Dec 19 2016
    GSK boosts board-level science as new CEO prepares to take over Dec 19 2016
    Phase III study start for closed triple in asthma Dec 19 2016
    GSK Starts Phase III Study of Once-Daily Closed Triple Combination Therapy FF/UMEC/VI in Patients... Dec 19 2016
    US drops bold warning from anti-smoking pills Chantix, Zyban Dec 16 2016
    Treasury Stock Dec 16 2016
    Director/PDMR Shareholding Dec 16 2016
    3 reasons to buy GlaxoSmithKline plc’s 5.5% yield before the market catches on Dec 12 2016
    Relvar® Ellipta® 100/25 mcg Gains Approval in Japan for Use in Patients with COPD Dec 02 2016
    Director/PDMR Shareholding Dec 01 2016
    Total Voting Rights Dec 01 2016
    GSK biotech asthma drug wins UK approval after extra price cut Nov 30 2016
    GlaxoSmithKline seeks U.S. approval for triple lung drug Nov 21 2016
    Ex-sleuths sue GlaxoSmithKline over imprisonment in China Nov 16 2016
    Ex-sleuths sue GlaxoSmithKline over imprisonment in China Nov 16 2016
    Ex-sleuths sue GlaxoSmithKline over imprisonment in China Nov 16 2016
    Sanofi, GSK expect further price pressure, more M&A under Trump Nov 15 2016
    Director/PDMR Shareholding Nov 10 2016
    Block listing Interim Review Nov 08 2016
    Director/PDMR Shareholding Nov 08 2016
    Director/PDMR Shareholding Nov 04 2016
    Director/PDMR Shareholding Nov 02 2016
    Total Voting Rights Nov 01 2016
    Director/PDMR Shareholding Oct 28 2016
    Director/PDMR Shareholding Oct 27 2016
    GlaxoSmithKline Pharmaceuticals Limited announces a 12% Sales growth for the quarter ended 30... Oct 27 2016
    Director/PDMR Shareholding Oct 26 2016
    GlaxoSmithKline beats forecasts as weak pound provides windfall Oct 26 2016
    GlaxoSmithKline beats forecasts as weak pound provides windfall Oct 26 2016
    Price Monitoring Extension Oct 26 2016
    GSK files potential $1 billion shingles vaccine for U.S. approval Oct 24 2016
    GSK files potential $1 billion shingles vaccine for U.S. approval Oct 24 2016
    GSK files potential $1 billion shingles vaccine for U.S. approval Oct 24 2016
    Zika vaccine race spurred by crisis and profit potential Oct 04 2016
    After CEO move, GSK picks ex-Novartis executive to head consumer unit Sep 29 2016
    Hard to swallow: emerging markets get tougher for drugmakers Sep 22 2016
    Hard to swallow: emerging markets get tougher for drugmakers Sep 22 2016
    Hard to swallow - emerging markets get tougher for drugmakers Sep 22 2016
    Breaking the mould: GSK picks Big Pharma's first female CEO Sep 20 2016
    Breaking the mould: GSK picks Big Pharma's first female CEO Sep 20 2016
    GlaxoSmithKline names insider Emma Walmsley as new CEO Sep 20 2016
    GlaxoSmithKline names insider Emma Walmsley as new CEO Sep 20 2016
    GlaxoSmithKline names insider Emma Walmsley as new CEO Sep 20 2016
    GSK sells anaesthetics to Aspen for up to $370 million Sep 12 2016
    GSK and Google parent forge $715 mln bioelectronic medicines firm Aug 01 2016
    In fight for GSK's Advair, generic firms step carefully on price Jun 03 2016
    Anti-graft group says drugmakers failing to tackle corruption Jun 01 2016
    GSK gets EU approval for first gene therapy for children May 27 2016
    GlaxoSmithKline promises reduced drug patents to help world's poor Mar 31 2016
    GlaxoSmithKline CEO Witty to bow out in March 2017 Mar 17 2016
    GSK dismisses near-term split as new drugs offset falling Advair Feb 03 2016
    Five charged in U.S. with stealing secrets from GlaxoSmithKline Jan 21 2016
    Amgen reacquires rights to three drugs from Glaxo in 48 countries Dec 14 2015
    GSK plan to file up to 20 new drugs by 2020 underwhelms market Nov 03 2015
    GlaxoSmithKline beats forecasts as HIV drugs, flu vaccines shine Oct 28 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)